Dong Ran
Finanzdirektor/CFO bei FENBI LTD.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Liang Wei | M | 39 |
Beijing Fenbi Bluesky Technology Co., Ltd.
 Beijing Fenbi Bluesky Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Fenbi Bluesky Technology Co., Ltd. provides educational and training services. The private company is based in Beijing, China. The Chinese company was founded in 2015 by Yong Li, Changzhen Guo, Xin Li. Xiao Long Zhang has been the CEO of the company since 2015. | 9 Jahre |
| Xiao Long Zhang | M | 41 |
Beijing Fenbi Bluesky Technology Co., Ltd.
Beijing Fenbi Bluesky Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Fenbi Bluesky Technology Co., Ltd. provides educational and training services. The private company is based in Beijing, China. The Chinese company was founded in 2015 by Yong Li, Changzhen Guo, Xin Li. Xiao Long Zhang has been the CEO of the company since 2015. | 9 Jahre |
| Li Tang | M | 61 |
Beijing Biostar Pharmaceuticals Co. Ltd.
 Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 22 Jahre |
| Kai Lin Liu | M | 41 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 4 Jahre |
| Kai Yiu Yuen | M | 44 |
Macquarie Group
| 14 Jahre |
| Yong Li | M | 49 |
Beijing Fenbi Bluesky Technology Co., Ltd.
Beijing Fenbi Bluesky Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Fenbi Bluesky Technology Co., Ltd. provides educational and training services. The private company is based in Beijing, China. The Chinese company was founded in 2015 by Yong Li, Changzhen Guo, Xin Li. Xiao Long Zhang has been the CEO of the company since 2015. | 9 Jahre |
| Quan Zhou | F | 38 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 15 Jahre |
| Dong Xiao Qiu | M | 62 |
University of Hong Kong
| 1 Jahre |
| Xin Li | M | 40 |
Beijing Fenbi Bluesky Technology Co., Ltd.
Beijing Fenbi Bluesky Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Fenbi Bluesky Technology Co., Ltd. provides educational and training services. The private company is based in Beijing, China. The Chinese company was founded in 2015 by Yong Li, Changzhen Guo, Xin Li. Xiao Long Zhang has been the CEO of the company since 2015. | 9 Jahre |
| Rong Guo Qiu | M | 62 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 22 Jahre |
| Cheng Zhang | M | 49 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 6 Jahre |
| Tao Wang | F | - |
Beijing Fenbi Bluesky Technology Co., Ltd.
Beijing Fenbi Bluesky Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Fenbi Bluesky Technology Co., Ltd. provides educational and training services. The private company is based in Beijing, China. The Chinese company was founded in 2015 by Yong Li, Changzhen Guo, Xin Li. Xiao Long Zhang has been the CEO of the company since 2015. | 4 Jahre |
| Yan Li | F | 47 |
Beijing Fenbi Bluesky Technology Co., Ltd.
Beijing Fenbi Bluesky Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Fenbi Bluesky Technology Co., Ltd. provides educational and training services. The private company is based in Beijing, China. The Chinese company was founded in 2015 by Yong Li, Changzhen Guo, Xin Li. Xiao Long Zhang has been the CEO of the company since 2015. | 7 Jahre |
| Hai Yan Sheng | F | 38 |
Beijing Fenbi Bluesky Technology Co., Ltd.
Beijing Fenbi Bluesky Technology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Fenbi Bluesky Technology Co., Ltd. provides educational and training services. The private company is based in Beijing, China. The Chinese company was founded in 2015 by Yong Li, Changzhen Guo, Xin Li. Xiao Long Zhang has been the CEO of the company since 2015. | 9 Jahre |
| Jia Yuan | M | 43 | 1 Jahre | |
| Shu Feng Zhang | M | 55 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 8 Jahre |
| Ri Xiang Kong | M | 47 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 21 Jahre |
| Li Xin Wang | M | 54 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 3 Jahre |
| Song Dong Meng | M | 54 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 2 Jahre |
| Chung Shing Lee | M | 57 | - | |
| Heng Xie | M | 65 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 2 Jahre |
| Pai Zhu | M | 31 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 3 Jahre |
| Yik Pun Chan | M | 42 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | - |
| Fei Peng | M | 50 |
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Suet Lun Leung | F | 40 |
University of Hong Kong
| 8 Jahre |
| Pui Yee Liao | F | 38 |
University of Hong Kong
| 11 Jahre |
| Ting Ting Wong | F | 41 |
University of Hong Kong
| 8 Jahre |
| Syaru Shirley Lin | M | 55 |
University of Hong Kong
| 5 Jahre |
| Ho Wang Tong | M | 41 |
University of Hong Kong
| 8 Jahre |
| King Yin Lai | M | 41 |
University of Hong Kong
| 5 Jahre |
| Wing Kit Chan | M | 41 |
University of Hong Kong
| 4 Jahre |
| Ben Ware | M | - |
Macquarie Group
| 10 Jahre |
| Yu Him Tang | M | 40 |
University of Hong Kong
| 5 Jahre |
| Douglas Arner | M | 54 |
University of Hong Kong
| 8 Jahre |
| Kwok Ho Tsui | M | 36 |
University of Hong Kong
| 6 Jahre |
| Wing Kin Chan | M | 43 |
University of Hong Kong
| 5 Jahre |
| Lick Keung Cheung | M | 45 |
University of Hong Kong
| 6 Jahre |
| Tak Yi Chan | F | 41 |
University of Hong Kong
| 5 Jahre |
| Lee Lam | M | 64 |
University of Hong Kong
| 4 Jahre |
| Lok Hey Wong | M | 41 |
University of Hong Kong
| 6 Jahre |
| Yuen Ting Yung | F | - |
University of Hong Kong
| 4 Jahre |
| Li Bin Tao | M | 47 |
University of Hong Kong
| 3 Jahre |
| Oi Lam Chan | F | 36 |
University of Hong Kong
| 4 Jahre |
| Geng Xiao | M | 61 |
University of Hong Kong
| 15 Jahre |
| Chen Pang Li | M | 41 |
University of Hong Kong
| 4 Jahre |
| Su Ho | M | 56 |
University of Hong Kong
| 2 Jahre |
| Bao Fu Zheng | M | 45 |
University of Hong Kong
| 3 Jahre |
| Siu Fung Tang | M | 42 |
University of Hong Kong
| 3 Jahre |
| Ka Yan Chan | F | 40 |
University of Hong Kong
| - |
| Faat Chi Wu | M | 38 |
University of Hong Kong
| 4 Jahre |
| Yun Tat Ho | M | 38 |
University of Hong Kong
| 4 Jahre |
| Wing Kei Yip | M | 39 |
University of Hong Kong
| 4 Jahre |
| Gary Or | M | - |
University of Hong Kong
| 4 Jahre |
| Wai King Tang | M | 77 |
University of Hong Kong
| 4 Jahre |
| Yiu Mo Cheng | M | 60 |
University of Hong Kong
| 1 Jahre |
| Ruoyu Wang | M | - |
University of Hong Kong
| 4 Jahre |
| Michael Sale | M | - |
Macquarie Group
| 2 Jahre |
| Seary Zhao | F | - |
University of Hong Kong
| 3 Jahre |
| Qingyi S. Drechsler | M | - |
University of Hong Kong
| 3 Jahre |
| Fung Shuen Sit | M | 76 |
University of Hong Kong
| 30 Jahre |
| Hui Dong | M | 40 |
University of Hong Kong
| 3 Jahre |
| Tak Yee Chen | F | 46 |
University of Hong Kong
| 4 Jahre |
| Long Yan Wong | F | 36 |
University of Hong Kong
| 3 Jahre |
| Sze Ho Chan | M | 36 |
University of Hong Kong
| 4 Jahre |
| Ting Hei Lee | M | 42 |
University of Hong Kong
| 1 Jahre |
| Jing Wang | F | 40 |
University of Hong Kong
| 3 Jahre |
| Tsze Wah Chan | M | 75 |
University of Hong Kong
| 1 Jahre |
| Ming Hon Yau | M | 45 |
University of Hong Kong
| 3 Jahre |
| Hin Yin Yu | M | 45 |
University of Hong Kong
| 1 Jahre |
| Chi Tak Fok | M | 48 |
University of Hong Kong
| 2 Jahre |
| Neo Zhang | M | - |
University of Hong Kong
| 3 Jahre |
| Chen Li Liu | M | 43 |
University of Hong Kong
| 3 Jahre |
| Chi Hing Chan | F | 50 |
University of Hong Kong
| 4 Jahre |
| Ming Pui Chong | M | 46 |
University of Hong Kong
| 1 Jahre |
| Kwok Hing Tse | M | 39 |
University of Hong Kong
| 4 Jahre |
| Kin Cheung Yung | M | 62 |
University of Hong Kong
| 1 Jahre |
| Siu Chung Chan | M | 49 |
University of Hong Kong
| 3 Jahre |
| Hoi Wah Lo | M | 41 |
University of Hong Kong
| 4 Jahre |
| Man Leong Chang | M | 46 |
University of Hong Kong
| 3 Jahre |
| Shuk Yee Lee | F | 57 |
University of Hong Kong
| 4 Jahre |
| Jia Chen Zhang | F | 35 |
University of Hong Kong
| 4 Jahre |
| Joyce Jiang | M | - |
University of Hong Kong
| 4 Jahre |
| Ka Wai Tsang | M | 37 |
University of Hong Kong
| 4 Jahre |
| Shun Yin Chan | M | 37 |
University of Hong Kong
| 3 Jahre |
| Wing Yuen Au | M | 47 |
University of Hong Kong
| 1 Jahre |
| Ka Chun Cheung | M | 41 |
University of Hong Kong
| 4 Jahre |
| Ka Ying Cheung | F | 37 |
University of Hong Kong
| 4 Jahre |
| Natalie Chiu | F | - |
University of Hong Kong
| 4 Jahre |
| U Ock Ng | M | 53 |
University of Hong Kong
| 3 Jahre |
| Bo Man Cheung | F | 36 |
University of Hong Kong
| 3 Jahre |
| Wai Man Lau | M | 37 |
University of Hong Kong
| 4 Jahre |
| Chi Fong | M | 49 |
University of Hong Kong
| 4 Jahre |
| Shujun Liu | M | 71 |
University of Hong Kong
| 4 Jahre |
| Po Ting Hung | F | 36 |
University of Hong Kong
| 4 Jahre |
| Kai Yao Yuk | M | 43 |
University of Hong Kong
| 4 Jahre |
| Zhou Hang Cui | M | - |
University of Hong Kong
| 1 Jahre |
| Xiao Chun Liu | M | 53 |
University of Hong Kong
| 2 Jahre |
| Qiang Xu | M | 56 |
University of Hong Kong
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Hong Kong | 76 | 77,55% |
| China | 20 | 20,41% |
| Cayman Islands | 11 | 11,22% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
